Education
About Us
Working with TipRanks
Follow Us
Brii Biosciences Limited (HK:2137)
:2137
2137 Stock Chart & Stats
HK$1.44
HK$0.04(3.74%)
At close: 4:00 PM EST
HK$1.44
HK$0.04(3.74%)
Day’s Range― - ―
52-Week RangeHK$1.05 - HK$3.09
Previous CloseN/A
Volume2.92M
Average Volume (3M)6.36M
Market Cap
HK$1.10B
Enterprise Value-HK$1.10B
Total Cash (Recent Filing)HK$2.07B
Total Debt (Recent Filing)HK$7.39M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Mar 20, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding733,900,600
10 Day Avg. Volume5,897,564
30 Day Avg. Volume6,360,478
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)12.38
P/FCF Ratio-1.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Brii Biosciences Limited News
2137 FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was HK$1.05 and its highest was HK$3.09 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is HK$1.10B.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Mar 20, 2026 which is in 67 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Aug 21, 2025. The company reported -HK$0.223 earnings per share for the quarter, beating the consensus estimate of -HK$0.302 by HK$0.078.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate is -0.07.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 733,900,600 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -HK$0.223 in its last earnings report, beating expectations of -HK$0.302. Following the earnings report the stock price went down -0.49%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in HK:2137
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
Technical Analysis
Genor Biopharma Holdings Limited
―
3D Medicines, Inc.
―
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Hightide Therapeutics Inc
―
Options Prices
Currently, No data available
---